Skip to Content

Join the 'Tardive Dyskinesia' group to help and get support from people like you.

Tardive Dyskinesia News

Related terms: Tardive, Dyskinesia

Teva Announces FDA Approval of Austedo (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults

Posted 30 Aug 2017 by Drugs.com

JERUSALEM--(BUSINESS WIRE) August 30, 2017 --Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults. Austedo was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017. Tardive dyskinesia is a debilitating and often irreversible movement disorder characterized by repetitive and uncontrollable movements of the tongue, lips, face, trunk and extremities. The condition affects about 500,000 people in the United States and can be caused by certain medications used to treat mental health conditions or gastrointestinal conditions. “We are pleased to bring forward this second indication for Austedo to treat the underserved tardive dyskinesia population,” said Michael Hayden, M.D., Ph.D. ... Read more

Related support groups: Tardive Dyskinesia, Austedo, Deutetrabenazine

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients

Posted 25 Aug 2017 by Drugs.com

EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Gocovri, previously granted orphan drug status by the FDA, is the first and only medicine approved by the FDA for this indication. "Gocovri's approval is an important advancement for the treatment of Parkinson's disease, as it is the first FDA-approved medicine for the treatment of dyskinesia in Parkinson's disease patients," said Rajesh Pahwa, M.D., Laverne & Joyce Rider Professor of Neurology at the Kansas Medical Center and Director, Parkinson's Disease Center of Excellence at the University ... Read more

Related support groups: Tardive Dyskinesia, Amantadine, Extrapyramidal Reaction, Gocovri

First Drug for Tardive Dyskinesia, Ingrezza (valbenazine), Approved

Posted 12 Apr 2017 by Drugs.com

WEDNESDAY, April 12, 2017 – Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration. The disorder is characterized by repetitive involuntary movements, usually of the jaw, lips and tongue. Affected people may stick out the tongue, smack the lips, involuntarily move the arms and legs, and have trouble breathing, the FDA said in a news release. The disorder may be a side effect of older antipsychotic medications to treat conditions such as schizophrenia, depression or bipolar disorder. It's not known why some users of these medications develop tardive dyskinesia, while others don't, the agency said. "Tardive dyskinesia can be disabling and can further stigmatize patients with mental illness," said Dr. Mitchell Mathis, director of the FDA's Division of Psychiatry Products. ... Read more

Related support groups: Tardive Dyskinesia, Ingrezza, Valbenazine

Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)

Posted 11 Apr 2017 by Drugs.com

SAN DIEGO, April 11, 2017 /PRNewswire/ – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). Ingrezza, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first and only FDA-approved product indicated for the treatment of adults with TD. "The often debilitating effects of tardive dyskinesia have left people feeling isolated and forgotten. The approval of Ingrezza represents a turning point for these patients and their care partners, offering a meaningful treatment where before there was little hope," said Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences. "For the past 20 years, Neurocrine has been devoted to developing treatments for difficult to manage conditions in underserved ... Read more

Related support groups: Tardive Dyskinesia, Ingrezza, Valbenazine

Ask a Question

Further Information

Related Condition Support Groups

Extrapyramidal Reaction

Related Drug Support Groups

propranolol, clonidine, ropinirole, pramipexole, bromocriptine, vitamin e, chlordiazepoxide, tetrabenazine, Ingrezza, view more... Austedo, Alpha E, Aquavite-E, E-Gems, E-600, Aqua Gem-E, Aqua-E, apomorphine, E-400 Clear, Nutr-E-Sol, Vita-Plus E Natural, Amino-Opti-E, Aquasol E, valbenazine, deutetrabenazine, E Pherol